Anoro Ellipta cleared in Japan

|By:, SA News Editor

The Japanese Ministry of Health, Labor and Welfare approves GlaxoSmithKline (GSK) and Theravance's (THRX) Anoro Ellipta (umeclidinium/vilanterol) for the relief of various symptoms of chronic obstructive pulmonary diseases in patients who require the concurrent use of a long-acting inhaled muscarinic antagonist and a long-acting inhaled beta2 agonist.

Anoro is a once-daily treatment comprised of two broncodilators. Umeclidinium is the muscarinic antagonist and vilanterol is the beta2 agonist.

Under the terms of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of $10M based on Japanese regulatory approval.